Literature DB >> 15205818

[Antibodies against vaccine-preventable diseases in pregnant women and their offspring. Measles, mumps, rubella, poliomyelitis, and varicella].

A Sauerbrei1, J Prager, A Bischoff, P Wutzler.   

Abstract

In the eastern part of Germany, the age of primigravid women has clearly increased since 1990. This may change the protection provided by antibodies in pregnant women as well as their newborns. The objective of the present study was to assess antibodies against vaccine-preventable viral infectious diseases in pregnant women and their offspring to draw conclusions about their protection. Maternal and cord blood samples of 290 women from the eastern part of Germany with a mean age of 28 years were analyzed for antibodies against measles, mumps, rubella, poliomyelitis, and varicella. The study showed that the pregnant women had detectable levels of antibodies against measles virus in 79%, against mumps virus in 96%, against rubella virus in 87%, against polioviruses types 1-3 in 62-64%, and against varicella-zoster virus (VZV) in 97% of the cases. The seroprevalence of the antibodies in the newborns were not significantly different from those of their mothers. When antibody titers of mothers and newborns were compared, significantly higher titers to VZV could be detected in the cord blood sera of newborns. It is suggested that the prevalence of antibodies against measles and poliomyelitis is insufficient to protect the newborns efficiently. An immunity gap of 13% against rubella in mothers results in a potential risk for a congenital rubella syndrome in newborns. Despite the high seroprevalence of rubella and chickenpox, there is considerable potential for infections during pregnancy and neonatal period.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15205818     DOI: 10.1007/s00103-003-0689-z

Source DB:  PubMed          Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz        ISSN: 1436-9990            Impact factor:   1.513


  6 in total

1.  Prevalence of anti-rubella, anti-measles and anti-mumps IgG antibodies in neonates and pregnant women in Catalonia (Spain) in 2013: susceptibility to measles increased from 2003 to 2013.

Authors:  P Plans; F de Ory; M Campins; E Álvarez; T Payà; E Guisasola; C Compte; K Vellbé; C Sánchez; M J Lozano; I Aran; A Bonmatí; R Carreras; M Jané; L Cabero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-10       Impact factor: 3.267

Review 2.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

3.  Seroprevalence of varicella-zoster virus among pregnant women in two teaching hospitals, Tehran, Iran.

Authors:  Mahshid Talebi-Taher; Maryam Kashanian; Katayoon Khalili
Journal:  Iran J Microbiol       Date:  2014-02

4.  Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization.

Authors:  Margarita Riera-Montes; Kaatje Bollaerts; Ulrich Heininger; Niel Hens; Giovanni Gabutti; Angel Gil; Bayad Nozad; Grazina Mirinaviciute; Elmira Flem; Audrey Souverain; Thomas Verstraeten; Susanne Hartwig
Journal:  BMC Infect Dis       Date:  2017-05-18       Impact factor: 3.090

5.  Seroprevalence of Measles-, Mumps-, and Rubella-specific antibodies in the German adult population - cross-sectional analysis of the German Health Interview and Examination Survey for Adults (DEGS1).

Authors:  Nicole Friedrich; Christina Poethko-Müller; Ronny Kuhnert; Dorothea Matysiak-Klose; Judith Koch; Ole Wichmann; Sabine Santibanez; Annette Mankertz
Journal:  Lancet Reg Health Eur       Date:  2021-06-05

6.  Seroprevalence of anti-rubella and anti-measles IgG antibodies in pregnant women in Shiraz, Southern Iran: outcomes of a nationwide measles-rubella mass vaccination campaign.

Authors:  Behnam Honarvar; Mohsen Moghadami; Afagh Moattari; Amir Emami; Neda Odoomi; Kamran Bagheri Lankarani
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.